HeraMED Ltd. (AU:HMD)
ASX:HMD
Want to see AU:HMD full AI Analyst Report?
Top Page
HeraMED Ltd.
(Sydney:HMD)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.04
▲(0.00% Upside)
Action:Reiterated
Date:04/14/26
The score is held back primarily by weak financial performance—persistent losses, recurring cash burn, and recent revenue contraction—despite improved gross margin and a cleaner (zero-debt) balance sheet. Technical indicators add some support with a positive trend and neutral-to-mild bullish momentum, but valuation is constrained by negative earnings and no dividend data.
Positive Factors
High Gross Margin
A sustained gross margin near 60% indicates strong unit economics and product-level profitability potential. This structural margin buffer gives the company scope to invest in sales and R&D while still moving toward operating leverage if fixed costs are controlled, supporting long-term scalability.
Negative Factors
Persistent Cash Burn
Consistent negative operating and free cash flow means the business consumes capital to operate, elevating funding and liquidity risk. Over the medium term this forces reliance on external financing or equity dilution and limits the company’s ability to self-fund growth initiatives or weather downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
A sustained gross margin near 60% indicates strong unit economics and product-level profitability potential. This structural margin buffer gives the company scope to invest in sales and R&D while still moving toward operating leverage if fixed costs are controlled, supporting long-term scalability.
Read all positive factors
HeraMED Ltd. (HMD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$45.14M
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)―
Beta (1Y)1.97
Revenue Growth-19.47%
EPS Growth62.28%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,157,486,600
10 Day Avg. Volume1,195,844
30 Day Avg. Volume1,958,766
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)27.61
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HeraMED Ltd. Business Overview & Revenue Model
Company Description
HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate...
How the Company Makes Money
null...
HeraMED Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 195.77K | 225.49K | 413.19K | 215.81K | 83.68K |
| Gross Profit | 99.78K | 135.29K | 248.12K | -214.69K | -219.50K |
| EBITDA | -2.56M | -3.35M | -3.97M | -3.17M | -3.93M |
| Net Income | ― | -3.40M | -4.50M | -4.88M | -5.71M |
Balance Sheet | |||||
| Total Assets | 994.94K | 2.78M | 2.01M | 4.19M | 4.57M |
| Cash, Cash Equivalents and Short-Term Investments | 914.65K | 3.13M | 723.29K | 2.64M | 3.55M |
| Total Debt | 282.39K | 815.96K | 209.37K | 179.53K | 3.41M |
| Total Liabilities | 559.96K | 1.06M | 1.55M | 1.30M | 4.13M |
| Stockholders Equity | 931.03K | 1.72M | 466.70K | 2.88M | -105.66K |
Cash Flow | |||||
| Free Cash Flow | -2.44M | -2.98M | -5.57M | -3.20M | -3.20M |
| Operating Cash Flow | -2.44M | -2.98M | -5.57M | -2.52M | -3.12M |
| Investing Cash Flow | 0.00 | 0.00 | -2.05K | -690.78K | -85.43K |
| Financing Cash Flow | 1.27M | 6.88M | 2.96M | 2.54M | 4.88M |
HeraMED Ltd. Technical Analysis
Negative
0.04
Price Trends
0.05
Negative
0.04
Negative
0.04
Positive
Market Momentum
>-0.01
Positive
39.35
Neutral
19.09
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HMD, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.35 is Neutral, neither overbought nor oversold. The STOCH value of 19.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HMD.
HeraMED Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$45.14M | -5.14 | -417.72% | ― | -19.47% | 62.28% | |
49 Neutral | AU$24.72M | -1.40 | -98.14% | ― | 14.88% | 35.94% | |
43 Neutral | AU$3.12M | -0.37 | -358.43% | ― | -52.22% | 44.79% | |
41 Neutral | AU$19.85M | -4.09 | -58.40% | ― | -7.00% | 44.55% | |
41 Neutral | AU$10.75M | -0.50 | 459.94% | ― | 15.99% | 32.67% |
* Healthcare Sector Average
AU:HMD
HeraMED Ltd.
0.04
0.03
290.00%
AU:UCM
Uscom Limited
0.01
>-0.01
-36.84%
AU:AT1
Atomo Diagnostics Ltd.
0.02
<0.01
10.00%
AU:ADR
Adherium Ltd.
―
―
―
AU:CBL
Control Bionics Ltd.
0.06
0.03
93.55%
HeraMED Ltd. Corporate Events
HeraMED Adds 2.5 Million Shares to ASX Quotation
May 11, 2026
HeraMED Ltd. has applied to the ASX for quotation of 2.5 million new ordinary fully paid shares, expanding its listed securities under code HMD. The additional shares, issued on May 11, 2026, arise from the exercise or conversion of existing optio...
HeraMED Accelerates U.S. Push as Philips Partnership and Lee Health Pilot Gain Traction
Apr 30, 2026
HeraMED has reported a pivotal March 2026 quarter marked by advancing its U.S. commercial push for the HeraCARE platform through a deepening partnership with Philips and a promising pilot with Florida-based Lee Health. The company is transitioning...
HeraMED Director Timothy Chapman Granted 2.5 Million Performance Rights
Apr 27, 2026
HeraMED Ltd. has disclosed a change in director Timothy Chapman’s indirect interest in the company, lodged under ASX listing rule requirements. The notice details his holdings via Inverness Capital Pty Ltd, where he is a director, shareholde...
HeraMED Issues 3 Million Unquoted Options Under Employee Scheme
Apr 27, 2026
HeraMED Limited has issued 3,000,000 unquoted options under an employee incentive scheme, with various exercise prices and expiry dates, as notified in an Appendix 3G filing to the ASX. The new options, which will not be quoted on the exchange, fo...
HeraMED Issues 4 Million Unquoted Performance Rights Under Staff Incentive Plan
Apr 27, 2026
HeraMED Ltd. has notified the market that it will issue 4,000,000 unquoted performance rights under its employee incentive scheme, with an issue date of 21 April 2026. The move underscores the company’s ongoing use of equity-based remunerati...
HeraMED Sets May AGM as It Advances Digital Maternity Care Platform
Apr 21, 2026
HeraMED Limited, a digital health company specialising in remote maternity care, develops and markets the HeraCARE platform, which combines hardware, software, and data analytics to deliver integrated, cost-efficient prenatal and postpartum monito...
HeraMED Issues 3 Million Unquoted Options Under Employee Incentive Scheme
Apr 10, 2026
HeraMED Ltd. has notified the market of the issue of 3,000,000 unquoted options under its employee incentive scheme, each exercisable at $0.0528 and expiring on 15 January 2030. The options, issued on 30 March 2026 and not intended to be quoted on...
HeraMED Director Increases Shareholding Through Share Placement
Apr 10, 2026
HeraMED Ltd. has reported a change in the shareholding of director Sharon Richardson, who increased her direct holding in the company through participation in a recent capital placement. Her fully paid ordinary shareholding rose from 2,200,003 to ...
HeraMED Issues 38.7 Million New Shares Under Cleansing Notice
Apr 2, 2026
HeraMED Limited has issued 38,699,315 new fully paid ordinary shares on 2 April 2026, relying on provisions that allow the placement without a formal prospectus-style disclosure to investors. The move expands the company’s share base and may...
HeraMED Seeks ASX Quotation for 38.7 Million New Shares
Apr 1, 2026
HeraMED Ltd. has applied to the ASX for quotation of 38,699,315 new fully paid ordinary shares under the ticker HMD. The securities form part of a transaction previously notified to the market, with the new shares issued on 2 April 2026.The move w...
HeraMED Sets May 2026 AGM Date and Deadline for Director Nominations
Mar 30, 2026
HeraMED Limited has scheduled its Annual General Meeting for 21 May 2026 at 9:00am AEST, and has set 9 April 2026 as the deadline for shareholders or other eligible parties to submit director nominations. The timing formalises the company’s ...
HeraMED Wins Near-Unanimous Shareholder Backing at Extraordinary General Meeting
Mar 26, 2026
HeraMED Limited reported that shareholders overwhelmingly approved all resolutions put to an Extraordinary General Meeting held on 26 March 2026 in Melbourne. The passed resolutions included ratifications of prior share and option issues, approval...
HeraMED Director Converts Performance Rights Into Ordinary Shares
Mar 16, 2026
HeraMED Ltd. has disclosed a change in director Anoushka Gungadin’s interests following the vesting and exercise of performance rights into ordinary shares. The update reflects a routine equity conversion that alters the mix of her holdings ...
HeraMED Issues 2.63 Million New Shares Under Cleansing Notice
Mar 11, 2026
HeraMED Limited has issued 2,633,860 new fully paid ordinary shares on 12 March 2026, using provisions that allow issuance without a full disclosure document under the Corporations Act. The company states it is fully compliant with financial repor...
HeraMED Seeks ASX Quotation for 2.63 Million New Shares
Mar 11, 2026
HeraMED Ltd. has applied to the ASX for quotation of 2,633,860 new ordinary fully paid shares under the ticker HMD. The securities, issued on 12 March 2026 following the exercise or conversion of existing options or other convertible instruments, ...
HeraMED Files Updated Corporate Governance Statement with ASX
Feb 27, 2026
HeraMED Ltd has lodged its updated corporate governance statement for the year ended 31 December 2025, confirming compliance with ASX Listing Rules that require disclosure of how it adheres to the ASX Corporate Governance Council’s recommend...
HeraMED Narrows Annual Loss Despite Revenue Decline and Weaker Asset Base
Feb 27, 2026
HeraMED Limited has reported a 10.3% decline in revenues from ordinary activities to $431,605 for the year ended 31 December 2025, while its net loss after tax narrowed by 24.8% to $4.13 million compared with the prior year. The company did not de...
HeraMED Highlights AI-Driven Women’s Health Strategy in Investor Presentation
Feb 26, 2026
HeraMED has released an investor presentation outlining its position as a leader in AI-enabled women’s health, leveraging an FDA-cleared device to deliver solutions from pregnancy through to chronic care. The update is intended to inform inv...
HeraMED Calls March EGM and Urges Shift to Digital Shareholder Communications
Feb 23, 2026
HeraMED Limited has called an Extraordinary General Meeting for 26 March 2026 in Hawthorn East, Victoria, and will provide the Notice of Meeting primarily via electronic distribution in line with updated provisions of the Corporations Act. The com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.